Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
ContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record
-
ContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
-
UPDATE: Maxim Group Downgrades ContraVir Pharma (CTRV) at Hold
-
ContraVir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
-
ContraVir Pharma (CTRV) Prices Shares/Warrant Offering at $1
-
ContraVir Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
-
Pre-Open Movers 04/20: (IMNP) (SCSS) (KCG) Higher; (PLXS) (WR) (PM) Lower (more...)
-
Maxim Group Reiterates Buy Rating and $4 PT on ContraVir Pharmaceuticals (CTRV); HBV Data at Upcoming Conference
-
Unusual 11 Mid-Day Movers 10/14: (CTRV) (FBMS) (MGT) Higher; (OPTT) (TAYD) (BIOC) Lower
-
ContraVir Pharma (CTRV) Gains Key Preclinical Antiviral Asset with Ciclofilin Pharna Deal; Maxim Affirms at 'Buy'
-
Notable Analyst Rating Changes 5/6: (ARIA) (MAC) (GM) Upgraded; (FRT) (WMB) (ZTS) Downgraded
-
Maxim Group Starts ContraVir Pharma (CTRV) at Buy

